
Lecanemab shows sustained benefits in slowing early Alzheimer's progression over five years.
New data from the Clarity AD study show that continuous treatment with lecanemab significantly slows the progression of early Alzheimer's disease over five years, reducing the risk of advancing to more severe stages by up to 49%. Patients with low ta...





